- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
GHRH Analog · Educational Resource
Understanding CJC-1295 and Growth Hormone Research
GHRH Analog
(Synthetic Peptide)
Investigational Application
Growth hormone release research
Administration Protocol
Subcutaneous (subQ), per study protocol
Want to learn more?
A licensed team will reach out to guide you through the research.
Book a consultation →GHRH Analog · Educational Resource
Understanding CJC-1295 and Growth Hormone Research
01 — Overview
What is CJC-1295?
CJC-1295 is a synthetic peptide classified as a growth-hormone-releasing hormone (GHRH) analog, engineered to extend the compound's half-life relative to native GHRH.
As an investigational compound, CJC-1295 has not received regulatory approval for therapeutic use in the Philippines or elsewhere. It should be understood strictly as a research compound studied in preclinical and clinical research contexts.
Within research literature, CJC-1295 is most frequently studied for its sustained growth hormone-releasing properties, often in combination with GHRP-class secretagogues, areas summarized further below.
02 — How it works
How It Works: GHRH Receptor Activation and Sustained Growth Hormone Signaling
As a GHRH receptor agonist, CJC-1295 is studied for its ability to stimulate the pituitary gland to release growth hormone, with structural modifications researchers associate with a longer duration of action than native GHRH.
Literature describes this extended-action profile as a key distinguishing feature relative to native GHRH, which researchers associate with more sustained growth hormone and IGF-1 elevation in study contexts.
Administration in Research
In clinical literature, CJC-1295 is evaluated as a subcutaneous injection administered within controlled research protocols, often studied alongside a GHRP such as ipamorelin. As an investigational compound, it has not received regulatory approval for therapeutic use, and research contexts differ from any at-home or self-directed use.
03 — Areas of research
Summary of Investigated Research Areas
Clinical and preclinical literature evaluates CJC-1295 across several key physiological parameters to map its biological interactions:
GHRH Receptor Signaling Pathways
Research literature evaluates how CJC-1295 binds to and activates the growth-hormone-releasing hormone (GHRH) receptor on the pituitary gland.
Growth Hormone Pulsatility Studies
Preclinical and clinical studies observe sustained growth hormone and IGF-1 levels following CJC-1295 administration in research models.
Drug Affinity Complex Research
Investigational literature examines the compound's modified structure, which researchers associate with an extended half-life relative to native GHRH.
Body Composition Studies
Research protocols track body composition measures over controlled study periods involving this compound class.
Combination Protocol Studies
Some literature explores CJC-1295 studied in combination with GHRP-class secretagogues such as ipamorelin.
Pharmacokinetic Profiling
Studies characterize the absorption and elimination profile of CJC-1295 in research settings.
04 — FAQ
Frequently Asked Questions
Ano ba talaga ang CJC-1295?
Ang CJC-1295 ay isang synthetic peptide na GHRH (growth-hormone-releasing hormone) analog. Pinag-aaralan ito sa research dahil sa mas matagal na duration of action kumpara sa natural na GHRH. Educational discussion lang ito, hindi sales o medical advice.
FDA-approved ba ito?
Hindi. Ang CJC-1295 ay fully investigational compound na wala pang regulatory approval para sa therapeutic use kahit saan.
Bakit madalas itong pinagsasama sa Ipamorelin?
Pinag-aaralan sa literature ang CJC-1295 (GHRH analog) at Ipamorelin (GHRP) nang magkasama dahil magkaibang receptor pathway ang tinatarget ng bawat isa, kaya’t pinag-aaralan ang posibleng complementary effect ng dalawa.
Pwede ba akong bumili nito dito?
Ang page na ito ay para sa educational purposes lamang. Hindi kami nagbebenta ng peptides dito online — kausapin ang isang lisensyadong healthcare provider para sa tamang gabay.
05 — References
References and Academic Literature
Teichman, S.L., et al. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. The Journal of Clinical Endocrinology & Metabolism.
Ionescu, M., & Frohman, L.A. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology & Metabolism.
Jette, L., et al. (2005). Hybrid Peptide Analogs of Human Growth Hormone-Releasing Factor (GRF) with Enhanced Duration of Action. Endocrinology.
i
Medical Education Disclaimer: This page is intended strictly for educational and informational purposes regarding the scientific history and development of chemical compounds. It does not constitute medical advice, promotion, or advertising of any prescription medication. Any therapeutic applications must be evaluated and managed exclusively by a licensed medical practitioner.
Getting started
How to Get Started?
1. Consult
Book a free consultation with our licensed healthcare team.
100 % online. Hassle-free. Convenient.
2. Real Human Assessment
Talk with Philippine-licensed doctors and get prescribed.
Always doctor-led—never just an online form.
Free consultation with licensed providers
3. Start your Program
Your medication is prepared and delivered to your doorstep.
No lock-ins. No hidden fees. No subscriptions.
Formulated in FDA-regulated pharmacies
4. Consistent care
Stay on track with regular weekly follow-ups. On your chosen communication platform.
Unlimited complementary follow-ups